Shilpa Medicare Ltd Announces Successful Completion of Phase 3 Clinical Trials for New Drug SML-007 Against NAFLD

Shilpa Medicare Ltd has announced the completion of patient recruitment for the Phase 3 clinical trial of its newly developed drug SML-007 for the treatment of non-alcoholic fatty liver disease (NAFLD). Dosing is expected to be completed by the end of Q1 and the study is anticipated to be concluded by end of Q2 of the current fiscal year. SML-007, an orally administered drug, shows superior anti-inflammatory and antifibrotic effects as demonstrated in pre-clinical studies. The drug's benefits include modifications to bile acid synthesis and action through the adiponectin receptor pathway.